Epilepsy, treatment antagonists

Drugs that act on the H3 receptor are being developed for the treatment of obesity, sleep disturbances, epilepsy and cognitive disorders. The ability of histamine to promote arousal, suppress appetite, elevate seizure threshold and stimulate cognitive processes implies that compounds able to enhance the release of neuronal histamine should mimic these effects. Several H3 antagonists currently in development demonstrate such activity and show promise as effective and novel therapeutic agents [40, 84-86]. Because H3 agonists suppress the release of... 

In addition to epilepsy, neuronal death due to the toxic effects of glutamate has also been implicated in cerebral ischaemia associated with multi-infarct dementia and possibly Alzheimer s disease. With the plethora of selective excitatory amino acid receptor antagonists currently undergoing development, some of which are already in clinical trials, one may expect definite advances in the drug treatment of neurodegenerative disorders in the near future. 

Fig. 10.2 Chemical structures of NMDA and AMPA antagonists used for the treatment of ischemic injury, epilepsy and head injury in human subjects. Eliprodil (a) ifenprodil (b) remacemide (c) selfotel (d) and aptiganel (e)...

Yen W., Williamson J., Bertram E. H., and Kapur J. (2004). A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus. Epilepsy Res. 59 43-50. 

Primaxin cilastatin imipenem. primidolol [ban, inn, usan] is a -adrenoceptor antagonist with antihypertensive, antiarrhythmic and antianginal properties, primidone [ban, inn, usan] (Mysoline ) is a pyrimidinedione closely related to the barbiturates, and its actions are similar to phenobarbitone. It is an anticonvulsant that can be used in oral antiepileptic treatment of all forms of epilepsy (except absence seizures) and of essential tremor. 

---